Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1
Study meets primary endpoint, comparing efficacy of an investigational once a month injectable two-drug regimen to the standard of care daily, three-drug regimenFull results from the studies will be p...
Page (1) of 1 - 08/15/18||
(August 15, 2018)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved